Scientific publications

Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity

Yuste JR (1,2), Bertó J (3), Del Pozo JL (4,5), Leiva J (5).
(1) Division of Infectious Diseases, Clinica Universidad de Navarra, Pamplona, Spain 
(2) Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain.
(3) Respiratory Medicine Service, Clinica Universidad de Navarra, Pamplona, Spain.
(4) Division of Infectious Diseases, Clinica Universidad de Navarra, Pamplona, Spain.
(5) Department of Clinical Microbiology, Clinica Universidad de Navarra, Pamplona, Spain. 

Magazine: The Journal of Antimicrobial Chemotherapy

Date: Dec 20, 2016

Internal Medicine [SP] Clinical Microbiology [SP] Infectious Diseases [SP] Pneumology

Tedizolid phosphate is a new and potent oxazolidinone prodrug that was recently approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible microorganisms. Furthermore, tedizolid has proven to be active against Mycobacterium tuberculosis1 and non-tuberculous mycobacteria, such as Mycobacterium abscessus.2

We present the first case of prolonged treatment with tedizolid after haematological toxicity and gastrointestinal intolerance with linezolid in a patient with pulmonary non-tuberculous mycobacterial infection.

A male patient in his seventies was diagnosed with a pulmonary infection caused by Mycobacterium avium intracellulare and Mycobacterium kansasii (American Thoracic Society/IDSA criteria). The antimicrobial susceptibility tests revealed that only ethambutol (MIC, 0.125 and 0.25 mg/L, respectively), clarithromycin (MIC, 0.5 and 0.008 mg/L), amikacin (MIC, 8 and 0.25 mg/L), co-trimoxazole (MIC, 0.032 and 0.001 mg/L) and oxazolidinones were active against both non-tuberculous mycobacteria. The therapeutic options available for our patient were limited to azithromycin, ethambutol and oxazolidinones given his previous gastrointestinal intolerance to clarithromycin and episode of renal toxicity with co-trimoxazole.

CITATION  J Antimicrob Chemother. 2016 Dec 20. pii: dkw484. doi: 10.1093/jac/dkw484

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra